



Dr Guilherme Werneck (Brasil)
Dra Carla Maia (Portugal)
Dra Anaiá Sevá (Brasil)
Dr Gad Baneth (Israel)

MONDAY August 1st		Time	TUESDAY August 2nd	WEDNESDAY August 3rd	THURSDAY August 4th	FRIDAY 27 August 5th	Time	SATURDAY August 6th
		7:00 - 8:00	REGISTRATION	REGISTRATION	REGISTRATION	REGISTRATION		
		8:00 - 9:00	PLENARY TALK #1	PLENARY TALK #2	PLENARY TALK#3	PLENARY TALK #4	8:30 - 9:30	PLENARY TALK #5
		9:00 - 9:30	SUCCESSFUL STORY #1	SUCCESSFUL STORY #2	SUCCESSFUL STORY #3	SUCCESSFUL STORY #4	9.30 - 10:00	COFEE BREAK
		9:30 - 10:00	COFEE BREAK				10:00 - 11:30	MEETING #4
		10:00 - 11:30	SATELITE SYMPOSIUMS (sessions 1 - 5)	SATELITE SYMPOSIUMS (sessions 12-16)	SATELITE SYMPOSIUMS (sessions 23-27)	SATELITE SYMPOSIUMS (sessions 33 - 38)	11:30 - 12:00.	AWARDS
		11:30 - 13:00	SATELITE SYMPOSIUMS (sessions 6 - 11)	SATELITE SYMPOSIUMS (sessions 17 - 22)	SATELITE SYMPOSIUMS (sessions 28 - 44)	SATELITE SYMPOSIUMS (sessions 39 - 44)		
		13:00 - 14:00	LUNCH	LUNCH	POSTER PRESENTATION Session 3	LUNCH	12:00 - 13:10	CLOSING LECTURE
14:00 - 19:00	REGISTRATION	14:00 - 15:30	SPECIAL MEETING #1	ROUND TABLE (1 - 4)	LUNCH/ FREE AFTERNOON	ROUND TABLE (5 - 8)	13:10 - 13:30	CLOSING REMARKS
		15:30 - 16:30	ORAL COMMUNICATIONS (sessions 1 - 7)	ORAL COMMUNICATIONS (sessions 15 - 21)		ORAL COMMUNICATIONS (sessions 29 - 35)		
		16: 30 - 17:30	POSTER PRESENTATION Session 1	POSTER PRESENTATION Session 2		POSTER PRESENTATION Session 4		
17:30 - 18.00	OPENING SESSION	17:30 - 18:00	COFEE BREAK		COFEE BREAK			
18:00 - 19:00	INAUGURAL LECTURE	18:00 - 19:00	ORAL COMMUNICATIONS (sessions 8 - 14)	ORAL COMMUNICATIONS (sessions 22 - 28)		ORAL COMMUNICATIONS (sessions 36 - 41)		
19:00 - 20:30	WELCOME RECEPTION							

MONDAY
August 1st

14:00 - 19:00

REGISTRATION

17:00 - 18:00

OPENING SESSION
(BOLIVAR AUDITORIUM)

18:00 - 19:00

INAUGURAL TALK
The pathway of visceral leishmaniasis elimination, lessons learnt for a huger challenge
Dr. Jorge Alvar, DNDi, Switzerland
(BOLIVAR AUDITORIUM)

19:00 - 20:30

WELCOME RECEPTION
(GARDENS)

TUESDAY (August 2nd)

AUDITORIUM	BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO
7:00 - 8:00	REGISTRATION						
8:00 - 9:00	Plenary talk #1	<p align="center">Fighting a chronic crisis in access and innovation <i>The role of DNDi in the development and delivery of treatments for leishmaniasis</i></p> <p align="center">Dr. Bernard Pécoul DNDi, Switzerland</p> <p align="center">Presenter: Carlos H. N. Costa Federal University of Piauí, Brazil</p>					
9:00 - 9:30	Successful experience #1	<p align="center">Human African Trypanosomiasis</p> <p align="center">Dr. Phillippe Neau Sanofi, France</p> <p align="center">Presenter: Carlos H. N. Costa Federal University of Piauí, Brazil</p>					
9:30 - 10:00	COFEE BREAK						
10:00 - 11:30	Satellites symposium (sessions 1 - 5)	<p>Symposium # 1: Role of asymptomatics in the transmission of leishmaniasis, sleeping sickness and Chagas disease</p> <p>Chair: Dr. Maria-Jesus Pinazo, DNDi, Switzerland Co-chair: Dr. Rafael Antonio Herazo Tapia, DNDi, Switzerland</p> <p>1. <i>Towards VL control. New diagnosis approaches to detect asymptomatic patients.</i> Dr. Eugenia Carrillo, Instituto de Salud Carlos III, Spain</p> <p>2. <i>Asymptomatic infections in Human African Trypanosomiasis: Is it a challenge for elimination?</i> Dr. Phillippe Neau, Sanofi, France</p> <p>3. <i>Clinical and epidemiological implications of people with T. cruzi infection without organ involvement</i> Dr. Maria-Jesus Pinazo, DNDi, Switzerland</p>	<p>Symposium # 2: New vaccines and immunotherapies for canine leishmaniasis</p> <p>Chair: Dr. Javier Moreno, Instituto de Salud Carlos III, Spain</p> <p>1. <i>Live attenuated vaccine for canine leishmaniasis</i> Dr. Hira Nakhasi, US FDA, USA</p> <p>2. <i>An effective nasal nanoparticulate immunotreatment against leishmaniasis in dogs</i> Dr. Didier Betbeder, Vaxinano, France</p> <p>3. <i>Immunological characteristic of LETIFend. A vaccine for preventing canine leishmaniasis</i> Dr. Jerónimo Carnés, LETI Pharma, Spain</p>	<p>Symposium # 3: Emerging foci and changing epidemiology of leishmaniasis</p> <p>Chair: Dr. Caryn Bern, University of California, USA</p> <p>1. <i>Our changing views of leishmaniasis</i> Dr. Caryn Bern, University of California, USA</p> <p>2. <i>Leishmaniasis in Sri Lanka: emergence and evolution over 3 decades</i> Dr. Nadira D. Karunaweera, University of Colombo, Sri Lanka</p> <p>3. <i>Changes in the demography, epidemiology and clinical presentation of leishmaniasis in Brazil</i> Dr. Lucas Carvalho, Federal University of Bahia and FIOCRUZ, Brazil</p> <p>4. <i>Leishmaniasis without sand flies: the unfolding story of Mundinia</i> Dr. Paul Bates, Lancaster University, UK</p>	<p>Symposium # 4: Eliminating VL as a public health problem in the WHO South-East Asia Region: the last mile challenges and opportunities through the new Regional Strategy</p> <p>Sponsored by: WHO SEARO</p> <p>Chair: Dr. Suman Rijal, WHO-SEARO Co-chair: Dr. Saurabh Jain, WHO Geneva</p> <p>1. <i>Progress, achievements, remaining challenges and the New Regional Strategy for VL elimination in the WHO South-East Asia Region</i> Dr. Aya Yajima, WHO-SEARO</p> <p>2. <i>Success factors and common elimination challenges in the Region</i> 2.1. <i>India: Implementation of newer treatment regimens – challenges</i> Dr. Tanu Jain, National Center for Vector Borne Disease Control, Government of India</p> <p>2.2. <i>Achievements, challenges and reassessing VL endemicity in non-program districts in Nepal</i> Dr. Chuman Lal Das Kebrat, Epidemiology and Disease Control Division, Nepal Dr. Surendra Uranw, B.P. Koirala Institute of Health Sciences, Dharan, Nepal</p> <p>2.3. <i>Bangladesh: Sustaining the elimination targets - the way forward</i> Dr. Nazmul Islam, Disease Control & Line Director, CDC, DGHS Mohakhali, Bangladesh Dr. Be-Nazir Ahmed, ASCEND, Bangladesh Dr. Sabera Sultana, WHO Bangladesh</p> <p>3. <i>Panel discussion - Partnerships, innovation needs and advocacy for acceleration to reach and sustain the elimination targets in South East Asia</i> Chair: Dr. Saurabh Jain, WHO Geneva Co-chair: Aya Yajima, WHO-SEARO</p> <p>Panelist: Dr. Suman Rijal, WHO-SEARO</p>	<p>Symposium # 5: Inflammasomes and Leishmania</p> <p>Chair: David L. Sacks, NIAID - NIH, USA</p> <p>1. <i>Innate immune sensors and inflammasomes in the Leishmania-macrophage interaction</i> Dr. Dario S. Zamboni, University of Sao Paulo, Brazil</p> <p>2. <i>CD8 T cells promote NLRP3 inflammasome activation and IL-1b release in cutaneous leishmaniasis</i> Dr. Fernanda O. Novais, The Ohio State University, USA</p> <p>3. <i>Immune circuitries that maintain dermis resident macrophages as replicative niches for Leishmania major in a strong Th1 environment</i> Dr. David L. Sacks, NIAID - NIH, USA</p> <p>4. <i>The immunoregulatory effects of iron in cutaneous leishmaniasis</i> Dr. Christian Bogdan, M.D., University Hospital of Erlangen and Friedrich-Alexander-University (FAU) Erlangen-Nürnberg</p>	

TUESDAY (August 2nd)

AUDITORIUM		BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO	
11:30 - 13:00	Satelites symposium (sessions 6 - 11)	<p>Symposium # 6:</p> <p>Pathogenesis of kala-azar</p> <p>Chair: Dr. Carlos H. N. Costa Federal University of Piauí, Brazil</p> <p>1. Pathogenesis of Visceral Leishmaniasis: The dog model Dr. Isadora Lima, FIOCRUZ, Brazil</p> <p>2. The mouse model Dr. Paul Kaye, University of York, UK</p> <p>3. Immunopathogenesis in humans Dr. Carlos H. N. Costa, Federal University of Piauí, Brazil</p>	<p>Symposium # 7:</p> <p>Innovation in R&D to contribute to VL elimination</p> <p>Sponsored by: DNDi</p> <p>Chair: Dr. Fabiana Alves, DNDi, Switzerland</p> <p>Co-chair: Glaucia Cota, FIOCRUZ, Brasil.</p> <p>1. Current context of VL control and elimination in the endemic regions, patients' needs and the development of new therapies Dr. Fabiana Alves, DNDi, Switzerland</p> <p>2. Future oral treatments for Visceral Leishmaniasis: LXE408, from discovery to first study in patients Dr. Florencia Segal, Novartis Institutes for BioMedical Research, Switzerland</p> <p>3. PK/PD modeling to optimize treatment regimens for VL Dr. Thomas Dorlo, Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital, Netherlands</p> <p>4. Bringing the treatment closer to the communities: test and treat approach by combining a point of care diagnostics with the new oral safe drugs Dr. Israel Cruz, National School of Public Health, CIBERINFEC, Instituto de Salud Carlos III, Spain</p> <p>5. PKDL treatment – why it is important for VL control and elimination, and the need for improved treatments Dr. Shyam Sundar, Institute of Medical Sciences, Banaras Hindu University, India</p>	<p>Symposium # 8:</p> <p>Sand fly saliva and immune response of bitten hosts</p> <p>Chair: Dr. Fabiano Oliveira NIAID - NIH, USA</p> <p>1. Immune response to salivary LinB13 and disease severity in tegumentary leishmaniasis Dr. Camila Indiani de Oliveira, Instituto Gonçalo Moniz-FIOCRUZ, Brazil</p> <p>2. Anti-saliva antibody production in naive dogs exposed to uninfected Lutzomyia longipalpis bites Dr. Claudia Brodskyn, Instituto Gonçalo Moniz-FIOCRUZ, Brazil</p> <p>3. Immune pathways overrepresented in the human skin triggered by bites of sand fly vector arthropods Dr. Fabiano Oliveira, NIAID - NIH, USA</p> <p>4. Humoral immune responses in people to bites of Old World sand flies Dr. Naomi Aronson, Uniformed Services University of the Health Sciences, USA</p>	<p>Symposium # 9:</p> <p>Eliminating VL in India: the last mile challenges and opportunities</p> <p>Sponsored by: Global Health Strategies and The Bill and Melinda Gates Foundation</p> <p>Chair: Dr. Harmeet Singh Grewal, Government of India</p> <p>Co-chair: Dr. Dhruv Pandey, WHO, India</p> <p>Special Guest: Mr. Banna Gupta, Hon'able Minister of Health and Family Welfare, Government of Jharkhand, India</p> <p>1. Elimination of VL as a Public Health problem - Addressing the last mile barriers Dr. Tanu Jain, Director - National Center for Vector Borne Disease Control, Government of India</p> <p>2. How Bihar brought kala azar to the threshold of elimination Mr. Sanjay Kumar Singh, Executive Director - SHS, Health Department, Government of Bihar, India</p> <p>3. Fighting the disease in a challenging terrain - VL in Jharjhand Mr. Arun Kumar Singh, Additional Chief Secretary, Government of Jharkhand, India</p> <p>4. VL elimination status and sustenance in Uttar Pradesh (India) Dr. Vinu Prakash Singh, Government of Uttar Pradesh</p> <p>5. VL Elimination as a Public Health Problem West Bengal Dr. Tushar Acharyya, Dept. of Health & Family Welfare, Government of West Bengal, India</p> <p>6. Advocacy and communications needs to enable the new regional VL strategy outcomes – Learnings from projects Dr. Anuj Ghosh, Global Health Strategies, India</p>	<p>Symposium # 10:</p> <p>New trends in the diagnosis of Chagas disease</p> <p>Chair: Dr. Alejandro Luquetti Institute for Tropical Pathology and Public Health, Brazil</p> <p>1. Utility of cellular immune markers in chronic chagasic heart disease Dr. John Mario González, Universidad de los Andes, Colombia</p> <p>2. Point-of-care molecular diagnosis of Chagas disease: from field to laboratory Dr. Alejandro Schijman, National Council of Science and Technology (CONICET), Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (INGEBI), Argentina</p> <p>3. Conventional serology and diagnosis of Chagas disease Dr. Alejandro Luquetti, Institute for Tropical Pathology and Public Health, Brazil</p>	<p>Symposium # 11:</p> <p>New insights in posttranscriptional regulation in Leishmania: Implications in the parasite development and disease control</p> <p>Chair: Dr. Barbara Papadopoulou Université Laval, Canada</p> <p>1. A central mechanism regulating mRNA abundance throughout the Leishmania development Dr. Barbara Papadopoulou, Université Laval, Canada</p> <p>2. Translation regulation of ribosomal protein mRNAs in Leishmania: novel roles for an eIF4F-like complex and associated RNA-binding proteins Dr. Osvaldo Pompilio De Melo, Institute Aggeu Magalhães-FIOCRUZ, Brazil</p> <p>3. Investigating trans-regulators of the Leishmania lifecycle Dr. Pegine Walrad, University of York, UK</p> <p>4. Exploring predicted noncoding RNAs as putative regulatory elements in the protozoan parasite Leishmania Dr. Angela Kaysel Cruz, University of São Paulo - Ribeirão Preto Medical School, Brazil</p>		
13:00 - 14:00	LUNCH								
14:00 - 15:30	Special meeting #1							<p>Special meeting # 1:</p> <p>The NTDs in the landscape of Global Health, the view of World's opinion leaders</p> <p>Sponsored by: DNDi</p> <p>Chair: Dr. Jorge Alvar DNDi, Switzerland</p> <p>Co-chair: Dr. Iván D. Vélez PECET-Universidad de Antioquia, Colombia</p> <p>1. Welcome remarks Dr. Ren Minghui WHO, Switzerland</p> <p>2. Dr. Peter Hotez Baylor College of Medicine, USA</p> <p>3. Bernard Pécoul DNDi, Switzerland</p> <p>4. Kayla Laserson The Bill and Melinda Gates Foundation, India</p>	
15:30 - 16:30	Oral communications (sessions 1 - 7)	<p>Oral communications Session #1 Canine Leishmaniasis</p> <p>Chair: Dr. Filipe Dantas-Torres Aggeu Magalhães Institute FIOCRUZ</p> <p>01-01 to 01-06</p>	<p>Oral communications Session #2 Drug Discovery & Development</p> <p>Chair: Dr. Sara Robledo, PECET, Universidad de Antioquia, Colombia</p> <p>02-01 to 02-06</p>	<p>Oral communications Session #3 Vaccines +T cell memory</p> <p>Chair: Maritza Jaramillo</p> <p>03-01 to 03-06</p>	<p>Oral communications Session #4 Pathogenesis</p> <p>Chair: Dr. Guy Caljon University of Antwerp Belgium</p> <p>04-01 to 04-06</p>	<p>Oral communications Session #5 Epidemiology:</p> <p>Chair: Dr. Sival Pinto Brandão Filho Instituto Aggeu Magalhães FIOCRUZ Pernambuco Brazil</p> <p>05-01 to 05-06</p>	<p>Oral communications Session #6 Biochemistry</p> <p>Dr. Alicia Ponte-Sucre Universidad Central de Venezuela Venezuela</p> <p>06-01 to 06-06</p>	<p>Oral communications Session #7 Clinical presentation</p> <p>Chair: Dr. Jaime Soto FUNDERMA / Dermatological Hospital of Jorochito Bolivia</p> <p>07-01 to 07-06</p>	

TUESDAY (August 2nd)

AUDITORIUM	BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO	
16:30 - 17:30	<p align="center"> POSTER PRESENTATION Session P1 Canine leishmaniasis: P1-001 to P1-012 Diagnosis: P1-013 to P1-038 Epidemiology: P1-039 to P1-051 Pathogenesis: P1-052 to P1-069 Molecular Biology: P1-070 to P1-105 Vectors: P1-106 to P1-119 </p>							
17:30 - 18:00	<p align="center">COFEE BREAK</p>							
18:00 - 19:00	<p align="center"> Oral communications (sessions 8-14) </p>	<p align="center"> Oral communications Session #8 Social Innovation / Implementation Research / Operative Research Chair: Dr. Alexandra Cossio Duque, CIDEIM, Colombia 08-01 to 08-06 </p>	<p align="center"> Oral communications Session #9 Drug Discovery & Development Chair: Sara M. Robledo Universidad de Antioquia Colombia 09-01 to 09-06 </p>	<p align="center"> Oral communications Session #10 Extracellular vesicles + microRNA Chair: Dr. Fracehuli Dagger Universidad Central de Venezuela Venezuela 010-01 to 010-06 </p>	<p align="center"> Oral communications Session #11 Control strategies Chair: Dr. Alejandro Llanos-Cuentas. Universidad Cayetano Heredia, Peru 011-01 to 011-06 </p>	<p align="center"> Oral communications Session #12 Epidemiology Chair: Dr. Lucas Carvalho Federal University of Bahia and Fiocruz Brazil 012-01 to 012-06 </p>	<p align="center"> Oral communications Session #13 Chair: Zelandia Fermín, Universidad Central de Venezuela Venezuela 013-01 to 013-07 </p>	<p align="center"> Oral communications Session #14 Diagnosis Chair: Dr. Carlos Muskus, PECET, Universidad de Antioquia Colombia 014-01 to 014-06 </p>

WEDNESDAY (August 3d)

AUDITORIUM		BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO ROOM	
7:00 - 8:00	REGISTRATION								
8:00 - 9:00	Plenary talk #2	<p align="center"><i>Understanding Leishmania: From the "omics" to the clinic</i></p> <p align="center">Dr. Phil Scott, University of Pennsylvania, USA</p> <p align="center">Presenter: Dr. Fernanda Novais</p>							
9:00 - 9:30	Successful experience #2	<p align="center"><i>VL elimination program Southeast Asia</i></p> <p align="center">Dr. Suman Rijal WHO - SEARO, India</p> <p align="center">Presenter: Dr. Shyam Sundar, Institute of Medical Sciences, Banaras Hindu University, India</p>							
9:30 - 10:00	COFEE BREAK								
10:00 - 11:30	Satellites symposium (sessions 12-16)	<p>Symposium # 12:</p> <p>VL/HIV coinfection: novel insights and emerging challenges</p> <p>Chair: Dr. Johan Van Griesven Institute of Tropical Medicine Antwerp, Belgium</p> <p>1. Hidden burden of tuberculosis in VL/HIV co infected patients: the experience in India Dr. Koert Ritmeijer, MSF, Netherlands</p> <p>2. Secondary prophylaxis in VL/HIV coinfection: who to start and when to stop Dr. Eugenia Carrillo, Instituto de Salud Carlos III, Spain</p> <p>3. Predicting visceral leishmaniasis in HIV infected patients in Ethiopia: first step towards a screen and treat strategy Dr. Ermias Diro, University of Washington, USA</p> <p>4. Prevention of VL in HIV infected patients in Ethiopia and India: a screen and treat strategy? Dr. Raman Mahajan, MSF, India</p> <p>5. Immunological determinants of recurrent VL relapse in HIV patients: beyond CD4 T cell count Dr. Wim Adriaensen, Institute of Tropical Medicine Antwerp, Belgium</p>	<p>Symposium # 13</p> <p>Atypical Cutaneous Leishmaniasis in America</p> <p>Chair: Dr. Jaime Soto FUNDERMA / Dermatological Hospital of Jorochito, Bolivia</p> <p>1. What does "Atypical" mean in CL? Dr. Jaime Soto, FUNDERMA / Dermatological Hospital of Jorochito, Bolivia</p> <p>2 "Atypical" clinical forms of Cutaneous Leishmaniasis Dr. Ernesto Rojas, Major University of San Simon, Bolivia</p> <p>3. Chronic relapsing cutaneous leishmaniases Dr. Jaime Soto, FUNDERMA / Dermatological Hospital of Jorochito, Bolivia</p> <p>4. Clinic and immunology of "atypical" CL in Brazil Dr. Paulo Machado, Federal University of Bahia, Brazil</p> <p>5. Comorbidities in chronic cutaneous leishmaniasis Dr. Edgar Marcelino de Carvalho, Universidade Federal da Bahia e FIOCRUZ Bahia, Brazil</p> <p>6. Immunology of atypical CL (non-ulcerated x <i>L. infantum</i>) Dr. Marcia Dalastra Laurenti, University of Sao Paulo, Brazil</p>	<p>Symposium # 14:</p> <p>Epidemiology of leishmaniasis in América</p> <p>Chair: Dr. Alejandro Llanos Cuentas Universidad Peruana Cayetano Heredia, Peru</p> <p>Co-chair: Dr. Félix J. Tapia Universidad Central de Venezuela, Venezuela</p> <p>1. <i>Surveillance strategies for leishmaniasis in the Southern Cone of America based on vector ecoepidemiology</i> Dr. Daniel Salomón, National Institute of Tropical Medicine, INMeT, ANLIS, MoH, Argentina</p> <p>2. <i>The key to understanding leishmaniasis epidemiology – The Zoonotic cycle</i> Dr. Jeffrey Shaw, Sao Paulo University, Brazil</p> <p>3. <i>Novel information on the transmission of cutaneous leishmaniasis</i> Dr. Horacio Cadena-Peña, PECET, Universidad de Antioquia, Colombia</p> <p>4. <i>How are parasite and host genetics affecting the transmission in CL?</i> Dr. Andrea Boggild, University of Toronto, Canada</p> <p>5. <i>Evidence and gaps in knowledge for the control of visceral leishmaniasis</i> Dr. Dorcas Lamounier, Federal University of Piauí, Brazil</p>	<p>Symposium # 15:</p> <p>Animal models for Visceral Leishmaniasis: Suitability and Applications</p> <p>Chair: Dr. Javier Carrión Universidad Complutense de Madrid, Spain</p> <p>1. <i>The beagle dog model in neoleish® pre-clinical vaccine development</i> Dr. Pedro Alcolea, Margarita Salas Biological Research Center, Spanish National Research Council, Spain.</p> <p>2. <i>Rodent models of sand fly-initiated visceral leishmaniasis expose important facets to the immune response that govern Leishmania dissemination and transmissibility</i> Dr. Shaden Kamhawi, NIAID, NIH, USA</p> <p>3. <i>Animal models to study live-attenuated Leishmania as vaccine candidates to tackle visceral leishmaniasis</i> Dr. Rubens Lima Do Monte Neto, Instituto René Rachou, FIOCRUZ, Brazil</p> <p>4. <i>Increased levels of cortisol are associated with the severity of experimental visceral leishmaniasis caused by "Leishmania (L.) infantum"</i> Dr. Alda Maria Da-Cruz, FIOCRUZ, Faculdade de Ciências Médicas/UERL, Brazil</p>	<p>Symposium # 16:</p> <p>Drug resistance and treatment failure in leishmaniasis: A 21st century challenge</p> <p>Chair: Dr. Alicia Ponte-Sucre Universidad Central de Venezuela, Venezuela</p> <p>1. <i>Parasite drug susceptibility and response to treatment in cutaneous leishmaniasis</i> Dr. Nancy G. Saravia, CIDEIM, Colombia</p> <p>2. <i>Cellular and proteomic features of Leishmania guyanensis strains refractory to pentavalent antimonial</i> Dr. Patricia Cuervo, FIOCRUZ, Brazil</p> <p>3. <i>Drug resistance in Leishmania: does it really matter?</i> Dr. Jean Claude DuJardin, Institute of Tropical Medicine Antwerp, Belgium</p>			

WEDNESDAY (August 3d)

AUDITORIUM		BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO ROOM
11:30 - 13:00	Satelites symposium (sessions 17 - 22)	<p>Symposium # 17:</p> <p>VL Elimination as a public health problem in India</p> <p>Sponsored by: PATH and The Bill and Melinda Gates Foundation</p> <p>Chair: Dr. Tanu Jain , National Center for Vector Borne Disease Control, Ministry of Health & Family Welfare, India</p> <p>Co-chair: Dr. Bhupendra Tripathi, Bill & Melinda Gates Foundation, India</p> <p><i>1. Retrospective overview of the VL elimination program and adaptive strategies for the next phase</i> Dr. Sridhar Srikantiah, CARE, India</p> <p><i>2. Experience of Kala-azar elimination Programme in India and roles of WHO in elimination journey</i> Dr. Dhruv Pandey, WHO, Switzerland</p> <p><i>3. Monitoring of VL transmission in the peri-elimination phase: the potential of serological surveys</i> Dr. Kristien Cloots, Institute of Tropical Medicine Antwerp, Belgium</p> <p><i>4. Is molecular xenomonitoring a useful tool for monitoring visceral leishmaniasis (VL) transmission in the peri-elimination phase?</i> Dr. Mary Cameron, London School of Hygiene & Tropical Medicine, UK</p>	<p>Symposium # 18:</p> <p>Vector competence and <i>Leishmania</i>-sand fly interactions</p> <p>Chair: Dr. Pter Volf Charles University, Czech Republic</p> <p><i>1. Leishmania co-opts IgM natural antibodies prevalent in vertebrate blood for genetic exchange in sand flies</i> Dr. Tiago Donatelli Serafim, NIAID, NIH, Unites States of America</p> <p><i>2. Lessons learned from experimental <i>Leishmania</i> hybridization</i> Dr. Isabelle Louradour, Institut Pasteur, France</p> <p><i>3. Experimental transmission of <i>Mundinia</i> and <i>Porcisia</i> by insect vectors -</i> Dr. Jovana Sadlova, Charles University, Czech Republic</p> <p><i>4. Sustained infection of New World sandfly vectors for different <i>Leishmania</i> species</i> Dr. Nagila F. C. Secundino, Instituto Rene Rachou - FIOCRUZ, Brazil</p>	<p>Symposium # 19:</p> <p>Drug target identification, validation and drug discovery</p> <p>Chair: Dr. Gerald Spaeth Institut Pasteur, France</p> <p><i>1. Current status and future opportunities for drug discovery for leishmaniasis</i> Dr. Charles Mowbray, DNDi, Switzerland</p> <p><i>2. A structure-based drug discovery program targeting leishmania glycogen synthase kinase 3</i> Dr. Jadel Müller Kratz, DNDi, Switzerland</p> <p><i>3. The use of multiple orthogonal methodologies to determine the mechanism of action of promising anti-leishmanial compounds</i> Dr. Marta Lopes Lima, University of Dundee, UK</p> <p><i>4. The macrophage lysine demethylase <i>lsd1</i> as a potential target for host-directed antileishmanial drug discovery</i> Dr. Maria Gutierrez-Sanchez, Institut Pasteur/Université Paris-Saclay, France</p> <p><i>5. Cyanotriazoles: rapid sterilizing kinetoplastid inhibitors</i> Dr. Srinivasa Rao, Novartis Institute for Tropical Diseases, USA</p>	<p>Symposium # 20:</p> <p>Leishmaniasis vaccine: past, present and future</p> <p>Chair: Dr. Farrokh Modabber Retired professor, USA</p> <p><i>1. Progress towards developing a safe and efficacious pan leishmania vaccine</i> Dr. Hira Nakhasi, USFDA, USA</p> <p><i>2. Neoleish, first naked DNA plasmid vaccine against <i>Leishmania infantum</i> in dogs</i> Dr. Elena Sotelo, CZV (Zendal), Spain</p> <p><i>3. Development of a cgmp grade process to produce live attenuated leishmania parasites as a pan-leishmania vaccine</i> Dr. Kamalleshwar Prasad Singh, Gennova Biopharmaceuticals Limited, India</p> <p><i>4. Immunization with centrin-deficient leishmania braziliensis does not confer protection against subsequent infection</i> Dr. Camila Indiani de Oliveira, FIOCRUZ Bahia, Brazil</p> <p><i>5. Singlet Oxygen-killed <i>Leishmania</i> are safe and effective vaccines and vaccine platform</i> Dr. Kwang-Poo Chang, Chicago Medical School/RFUMS, USA</p>	<p>Symposium # 21:</p> <p>New guideline for the treatment of leishmaniasis in the Americas: what has changed?</p> <p>Organiced by: PAHO/WHO</p> <p>Chair:Chair: Dr. Jaime Soto FUNDERMA / Dermatological Hospital of Jorochito, Bolivia</p> <p><i>1. Recommendations for the treatment of leishmaniasis in the Americas</i> Dr. Glauca Fernandes Cota, FIOCRUZ MINAS, Brazil Dr. René Rachou Institute, FIOCRUZ, Brazil</p> <p><i>2. Recommendations for the treatment of cutaneous and mucosal leishmaniasis in the Americas</i> Dr. Jaime Soto, FUNDERMA / Dermatological Hospital of Jorochito, Bolivia</p> <p><i>3. Recommendations for the treatment of visceral leishmaniasis and VL-HIV co-infection in the Americas</i> Dr. Dorcas Lamounier Costa, Federal University of Piaui, Brazil</p>	<p>Symposium # 22:</p> <p>Molecular pathology and stratification of leishmaniasis</p> <p>Chair: Dr. Paul Kaye University of York, UK</p> <p><i>1. Dissecting the immune landscape of Post kala-azar Dermal Leishmaniasis</i> Dr. Mitali Chatterjee, Institute of Postgraduate Medical Education & Research, India</p> <p><i>2. CD8 T cells and hypoxia in cutaneous leishmaniasis</i> Dr. Fernanda O. Novais, The Ohio State University, USA</p> <p><i>3. Regulation of inflammatory response in patients with cutaneous leishmaniasis</i> Dr. Lucas Carvalho, Federal University of Bahia and FIOCRUZ, Brazil</p> <p><i>4. Unraveling the immunological signatures of healing responses to optimize therapeutics for cutaneous leishmaniasis</i> Dr. Maria Adelaida Gómez, CIDEIM, Colombia</p>	
		13:00 - 14:00		LUNCH				

WEDNESDAY (August 3d)

AUDITORIUM		BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO ROOM
14:00 - 15:30	Roud table (Session 1-4)	<p>RT # 1:</p> <p>From prevention of canine leishmaniasis to control of human VL</p> <p>Chair: Dr. Guilherme Werneck State University of Rio de Janeiro and Federal University of Rio de Janeiro, Brazil</p> <p>1. <i>Effects and challenges of reservoir interventions for visceral leishmaniasis control in Brazil</i> Dr. David Soeiro Barbosa, Federal University of Minas Gerais, Brazil</p> <p>2. <i>Prevention of canine leishmaniasis using topical insecticides -</i> Dr. Gad Baneth, The Hebrew University of Jerusalem, Israel</p> <p>3. <i>Canine and human leishmaniasis in europe: epidemiological overview and perception of veterinary and public health authorities about their control and emergence</i> Dr. Carla Maia, Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Portugal</p> <p>4. <i>Mathematical modelling studies on the prevention/control zoonotic VL in dogs and humans</i> Dr. Anaiá da Paixão Sevá, State University of Santa Cruz, Brazil</p>	<p>RT # 2:</p> <p>Leishmaniasis control and elimination: progress and perspectives</p> <p>Chair: Dr. Nirmal Kumar Ganguly National Academy of Medical Sciences, India</p> <p>Co-chair: Dr. Daniel Argaw Dagne WHO, Switzerland</p> <p>1. <i>Overview of leishmaniasis control/elimination: progress to date</i> Dr. Daniel Argaw Dagne, WHO, Switzerland</p> <p>2. <i>Diagnostics in leishmaniasis: key advances, unmet needs and limitations</i> Dr. Israel Cruz, Instituto de Salud Carlos III, Spain</p> <p>3. <i>Headway and Gaps in Innovative Vector Control Approaches suited to Eco-Epidemiological Settings</i> Dr. Dia-Eldin Elnaiem, University of Maryland Eastern Shore, USA</p> <p>4. <i>Treatment in visceral and cutaneous leishmaniasis: advances, gaps and challenges</i> Dr. Fabiana Alves, DNDi, Switzerland</p> <p>5. <i>Partners perspective for VL control/elimination support</i> Dr. Jordan Tappero, Bill and Melinda Gates Foundation</p> <p>6. <i>Perspectives of the global leishmaniasis control/elimination in line with NTD roadmap 2030</i> Dr. Saurabh Jain, WHO, Switzerland</p>	<p>RT # 3</p> <p>Access to diagnosis and treatments for vulnerable groups.</p> <p>Chair: Dr. Margriet den Boer MSF, UK</p> <p>Co-chair: Duncan Ochol, The END Fund, Kenya</p> <p>1. Strategies to improve access to diagnosis and treatment for VL in South Sudan Dr. Mounir Christo Lado, Inter-Church Medical Assistance (IMA) World Health, South Sudan</p> <p>2. Access to CL care in Pakistan Suzette Kamink, MSF, Pakistan</p> <p>3. VL outbreak response Dr. Duncan Ochol, The END Fund, Kenya</p> <p>4. Access to care for HIV-VL in India Dr. Raman Mahajan, MSF, India</p>			<p>RT # 4:</p> <p>The LEAP, an ongoing experience</p> <p>Sponsored by: DNDi</p> <p>Chair: Dr. Monique Wasunna DNDi, Africa Regional Office, Kenya</p> <p>1. <i>The impact of VL in the health agenda, a perspective from the Kenya Ministry of Health</i> Dr. Sultani Matendecheo, Ministry of Health, Kenya</p> <p>2. <i>A new strategy for treating VL in Eastern Africa, the PM-MIL combination</i> Prof. Ahmed Musa, University of Khartoum, Sudan</p> <p>3. <i>Cutaneous Leishmaniasis in Eastern Africa, why it should no longer be neglected</i> Dr. Endalamaw Gadisa Belachew, Armauer Hansen Research Institute, Ethiopia</p> <p>4. <i>The LEAP, from a research platform towards access</i> Dr. Simon Bolo, DNDi, Africa Regional Office, Kenya</p>	
15:30 - 16:30	Oral communications (sessions 15-21)	<p>Oral communications Session #15</p> <p>Drug Discovery & Development:</p> <p>Chair: Dr. Sara Robledo, Cideim, Colombia</p> <p>015-01 to 015-06</p>	<p>Oral communications Session #16</p> <p>Social Innovation / Implementation Research / Operative Research</p> <p>Chair: Dr. Mady Barbeitas CERMES 3/ Inserm, France</p> <p>016-01 to 016-06</p>	<p>Oral communications Session #17</p> <p>Immunology/Cell Biology/Pathogenesis</p> <p>Chair: Dr. Marcel Marín 017-01 to 017-06</p>	<p>Oral communications Session #18</p> <p>Pathogenesis</p> <p>Chair: Dr. Hamlet Acevedo, Institut National de la Recherche Scientifique, Canadá</p> <p>018-01 to 018-06</p>	<p>Oral communications Session #19</p> <p>Epidemiology and virus</p> <p>Chair: Dr. Alexis Mendoza-León, Universidad Central de Venezuela Venezuela</p> <p>019-01 to 019-06</p>	<p>Oral communications Session #20</p> <p>Molecular Biology / Regulation</p> <p>Chair: Dr. María Adelaida Gómez, CIDEIM Colombia</p> <p>020-01 to 020-06</p>	<p>KALAMARY ROOM</p> <p>Oral communications Session #21</p> <p>Diagnosis</p> <p>Chair: Dr. Carlos Muskus PECET, Universidad de Antioquia Colombia</p> <p>021-01 to 021-06</p>
16:30 - 17:30	<p>POSTER PRESENTATION</p> <p>Session P2</p> <p>Canine leishmaniasis: P2-001 to P2-009.1 Treatment and Resistance: P2-010 to P2-024 Drug Discovery & Development: P2-025 to P2-052. Immune response: P2-053 to P2-072 Epidemiology: P2-073 to P2-082 Genetics/Genomics: P2-083 to P2-098 Social Innovation/Implementation research/Operative research: P2-099 to P2-111</p>							
17:30 - 18:00	<p>COFEE BREAK</p>							



WEDNESDAY (August 3d)

AUDITORIUM		BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO ROOM
18:00 - 19:00	<p align="center">Oral communications (sessions 22-28)</p>	<p align="center">Oral communications Session #22</p> <p align="center">Drug Discovery & Development</p> <p align="center">Chair: Dr. Alicia Ponte-Sucre. Universidad Central de Venezuela Venezuela</p> <p align="center">022-01 to 022-06</p>	<p align="center">Oral communications Session #23</p> <p align="center">Vectors & Reservoirs</p> <p align="center">Chair: Dr. Guy Caljon University of Antwerp Belgium</p> <p align="center">023-01 to 023-06</p>	<p align="center">Oral communications Session #24</p> <p align="center">Control strategies</p> <p align="center">Chair: Dr. Alejandro Llanos-Cuentas Universidad Cayetano Heredia Peru</p> <p align="center">024-01 to 024-06</p>	<p align="center">Oral communications Session #25</p> <p align="center">Canine leishmaniasis</p> <p align="center">Chair: Dr. Javier Carrión Universidad Complutense de Madrid Spain</p> <p align="center">025-01 to 025-06</p>	<p align="center">Oral communications Session #26</p> <p align="center">Genomics and transcriptome</p> <p align="center">Chair: Dr. Fracehuli Dagger Universidad Central de Venezuela Venezuela</p> <p align="center">026-01 to 026-06</p>	<p align="center">Oral communications Session #27</p> <p align="center">Molecular Biology</p> <p align="center">Chair: Dr. Patricia Cuervo Fiocruz Brazil</p> <p align="center">027-01 to 027-06</p>	<p align="center">KALAMARY ROOM Oral communications Session #28</p> <p align="center">Treatment and Resistance</p> <p align="center">Chair: Dr. Jean Claude Dujardin, Institute of Tropical Medicine Antwerp Belgium</p> <p align="center">028-01 to 028-06</p>

THURSDAY (August 4th)

THURSDAY (August 4th)								
AUDITORIUM	BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO	
7:00 - 8:00	REGISTRATION							
8:00 - 9:00	Plenary talk # 3	<p align="center"><i>Impact of armed conflict and displacement on the occurrence of leishmaniasis</i></p> <p align="center">Dr. Koert Ritmeijer MSE, Netherlands</p> <p align="center">Presenter: Dr Jean Claude Dujardin, Institute of Tropical Medicine Antwerp, Belgium</p>						
9:00 - 9:30	Successful experience #3	<p align="center"><i>Chagas Disease: A success story?</i></p> <p align="center">Dr. Felipe Guhl, CIMPAT - Universidad de los Andes, Colombia</p> <p align="center">Presenter: Dr. Alejandro Luquetti, Institute for Tropical Pathology and Public Health, Brazil</p>						
9:30 - 10:00	COFFEE BREAK							
10:00 - 11:30	Satellites symposium (sessions 23-27)	<p>Symposium # 23:</p> <p>Future prospects in the treatment of cutaneous leishmaniasis form</p> <p>Sponsored by: DNDi</p> <p>Chair: Dr. Byron Arana DNDi, Switzerland</p> <p>Co-chair: Dr. Max Groggl Naval Medical Research Center, USA</p> <p>1. <i>Is there a place for immunomodulators in the treatment of CL?</i> Dr. Paulo Roberto Lima Machado, Universidade Federal da Bahia, Brazil</p> <p>2. <i>Building the pathway for translational drug development of orally active new chemical entities for cutaneous leishmaniasis</i> Dr. Jadel Muller Kratz, DNDi, Switzerland</p> <p>3. <i>Topical paromomycin in cutaneous leishmaniasis: supportive clinical data and a regulatory roadmap</i> Dr. Armand Balboni, US Air Force Academy; Appili Therapeutics, USA</p> <p>4. <i>Unmet needs in cutaneous leishmaniasis diagnosis and 2030 Road Map Targets</i> Dr. Israel Cruz, Instituto de Salud Carlos III, Spain</p>	<p>Symposium # 24:</p> <p>Leishmaniasis and Movement: Imported leishmaniasis by travelers and migrants</p> <p>Chair: Dr. Naomi E. Aronson, Uniformed Services University of the Health Sciences, USA</p> <p>1. <i>Groups at risk, main geographical areas of acquisition of imported leishmaniasis</i> Dr. Andrea K. Boggild, Toronto General Hospital and University of Toronto, Canada</p> <p>2. <i>Diagnosis: the importance of typing the parasite of imported leishmaniasis</i> Dr. Javier Moreno, Instituto de Salud Carlos III, Spain</p> <p>3. <i>Clinical Diversity of Imported Leishmaniasis</i> Dr. Naomi E. Aronson, Uniformed Services University of the Health Sciences, USA</p> <p>4. <i>Targeted treatment of imported leishmaniasis</i> Dr. Rogelio López-Vélez, Ramón y Cajal Institute for Health Research (IRyCIS), Ramón y Cajal University Hospital, Spain</p>	<p>Symposium # 25:</p> <p>Biomarkers for diagnosis of leishmaniasis</p> <p>Chair: Eugenia Carrillo Instituto de Salud Carlos III, Spain</p> <p>1. <i>Biomarkers in visceral leishmaniasis patients coinfecting with HIV</i> Dr. Wim Adriaensen, Institute of Tropical Medicine Antwerp, Belgium</p> <p>2. <i>Biomarkers in PKDL</i> Dr. Eduard E Zijlstra, Rotterdam Center for Tropical Medicine, Netherlands</p> <p>3. <i>Diagnosis of visceral leishmaniasis in an elimination setting: a validation study of the diagnostic algorithm in India</i> Dr. Shyam Sundar, Institute of Medical Sciences, Banaras Hindu University, India</p>	<p>Symposium # 26:</p> <p>Cell Biology and Leishmania infection</p> <p>Chair: Dr. Albert Descoteaux Institut National de la Recherche Scientifique, Canada</p> <p>1. <i>The interplay between toll-like receptors and serine peptidases in the L. donovani infection</i> Dr. Ana Paula Lima, Universidade Federal do Rio de Janeiro, Brazil</p> <p>2. <i>Macrophage mitochondrial biogenesis and metabolic reprogramming induced by L. donovani required lipophosphoglycan and type I interferon signaling.</i> Dr. Hamlet Acevedo Ospina, INRS - Centre Armand-Frappier Santé Biotechnologie, Canada</p> <p>3. <i>RNAseq analysis revealed in bone marrow cells of susceptible dogs naturally infected with Leishmania infantum modulation in cell migration and DNA double-break repair pathways</i> Dr. Patricia Veras, Gonçalo Moniz Institute-FIOCRUZ Bahia, Brazil</p>		<p>Symposium # 27:</p> <p>Leishmania Extracellular Vesicles: Impact on disease progression</p> <p>Chair: Dr. Martin Olivier McGill University, Canada</p> <p>1. <i>Extracellular vesicles from New World species of Leishmania: role during interaction with macrophages and human peripheral blood mononuclear cells (PBMCs)</i> Dr. Rodrigo Soares, FIOCRUZ René-Rachou, Brazil</p> <p>2. <i>EV-driven genetic exchange as a novel mechanism of drug resistance in eukaryotic parasites</i> Dr. Christopher Fernandez-Prada, Université de Montréal, Canada</p> <p>3. <i>Leishmania Exosomes and its Vector: Impact on Cutaneous Leishmaniasis</i> Dr. Martin Olivier, McGill University, Canada</p>	

THURSDAY (August 4th)

AUDITORIUM		BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO
11:30 - 13:00	<p align="center">Satelites symposium (sessions 28-32) Special Meeting #2</p>	<p>Symposium # 28: Vector surveillance and control for VL elimination</p> <p>Sponsored by Liverpool School of Tropical Medicine and The Bill and Melinda Gates Foundation</p> <p>Chair: Dr. Kalpana Baruah, National Center for Vector Borne Diseases Control, Ministry of Health & Family Welfare, Government of India, India</p> <p>Co-chair: Dr. Rudra Pratap Singh, Liverpool School of Tropical Medicine, UK</p> <p><i>1. Integrated ACD implementation- Uttar Pradesh Experience</i> Dr. Amresh Kumar, PATH, India</p> <p><i>2. Insights into successful IRS operations in Bihar and Jharkhand: 2012-2022</i> Dr. Bikas Sinha, CARE, India</p> <p><i>3. Effective surveillance leading to effective vector control policy change - what are the next challenges</i> Dr. Michael Coleman, Liverpool School of Tropical Medicine, UK</p> <p><i>4. New tools for improving vector control</i> Dr. Rudra Pratap Singh, Liverpool School of Tropical Medicine, UK</p> <p><i>5. Modelling the contribution of IRS to elimination of visceral leishmaniasis in the Indian sub-continent</i> Dr. Luc Coffeng, University Medical Center Rotterdam, Netherlands</p> <p><i>6. Integrated Entomological Surveillance – The way forward</i> Dr. Kalpana Baruah, National Center for Vector Borne Diseases Control, Ministry of Health & Family Welfare, Government of India, India</p>	<p>Symposium # 29: A Global Visceral Leishmaniasis Data Platform</p> <p>Sponsored by: IDDO</p> <p>Chair: Dr. Philippe Guérin, University of Oxford, UK</p> <p><i>1. Key challenges and opportunities</i> Dr. Mitali Chatterjee, Institute of Postgraduate Medical Education & Research, India</p> <p><i>2. Optimising historical data and planning prospectively</i> Dr. Ahmed Musa, University of Khartoum, Sudan</p> <p><i>3. Data platform potential for drug development</i> Dr. Fabiana Alves, DNDi, Switzerland</p> <p><i>4. Impact on policy</i> Dr. Saurabh Jain, WHO, Switzerland</p> <p><i>5. Future benefits of the VL Data Platform for research</i> Dr. Philippe Guérin, University of Oxford, UK</p>	<p>Symposium # 30: Immunopathogenesis and host-directed therapies in leishmaniasis</p> <p>Chair: Dr. Fernanda O. Novais, The Ohio State University, USA</p> <p><i>1. Maintenance of leishmania-specific memory cd4+ t cells requires constant antigen stimulation</i> Dr. Jude Uzonna, Max Rady College Of Medicine, University Of Manitoba, Canada</p> <p><i>2. Protective cd4+ th1 cell-mediated immunity is reliant upon execution of effector function prior to the establishment of the pathogen niche</i> Dr. Nathan Peters, University of Calgary, Canada</p> <p><i>3. Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of visceral leishmaniasis</i> Dr. Chris Engwerda, QIMR Berghofer Medical Research Institute, Australia</p> <p><i>4. Pathogenic CD4+ T cells associated with bone marrow dysfunction in experimental visceral leishmaniasis</i> Dr. Paul Kaye, University of York, UK</p>	<p>Symposium # 31: Reservoirs of leishmaniasis</p> <p>Chair: Dr. Filipe Dantas-Torres, Aggeu Magalhães Institute, FIOCRUZ, Brazil</p> <p><i>1. Wild and domestic reservoirs of Leishmania spp. in Brazil</i> Dr. Filipe Dantas-Torres, Aggeu Magalhães Institute, FIOCRUZ, Brazil</p> <p><i>2. Leishmania vs Sauroleishmania: role of reptiles in the epidemiology of leishmaniasis</i> Dr. Jairo Alfonso Mendoza Roldán, University of Bari, Italy</p> <p><i>3. Other reservoirs of Leishmania infantum in Europe and their role in the control of canine and human leishmaniasis</i> Dr. Domenico Otranto, University of Bari, Italy</p> <p><i>4. Source or sink – not an easy decision</i> Dr. Jeffrey Shaw, Sao Paulo University, Brazil</p>	<p>Symposium # 32: Genomics and epidemiological surveillance</p> <p>Chair: Dr. Jean-Claude Dujardin, Institute of Tropical Medicine Antwerp, Belgium</p> <p>Co-chair: Elisa Cupolillo, FIOCRUZ, Brazil</p> <p><i>1. Genome diversity in Neotropical Leishmania: colonization and hybridization</i> Dr. Elisa Cupolillo, FIOCRUZ, Brazil</p> <p><i>2. Leishmaniasis in Sri Lanka: Parasite and host determinants</i> Dr. Nadira Karunaweera, University of Colombo, Sri Lanka</p> <p><i>3. Direct sequencing in host tissues for genomic surveillance of leishmaniasis</i> Dr. Malgorzata A. Domagalska, Institute of Tropical Medicine Antwerp, Belgium</p> <p><i>4. Metagenomics of Phlebotomus papatasi and Lutzomyia longipalpis</i> Dr. Mary Ann McDowell, University of Notre Dame, USA</p>		
13:00 - 14:00	<p>POSTER PRESENTATION</p> <p>Session P3</p> <p>Canine leishmaniasis: P3-001 to P3-010 Clinic: P3-011 to P3-027 Treatment: P3-028 to P3-037.1 Drug Discovery & Development: P3-038 to P3-046 Epidemiology: P3-047 to P3-057 Pathogenesis: P3-058 to P3-078 Biochemistry: P3-079 to P3-097 Genetic/Genomic: P3-098 to P3-102 Vectors: P3-103 to P3-110</p>							
14:00 - 19:00	<p>LUNCH/ FREE AFTERNOON</p>							

FRIDAY (August 5th)

AUDITORIUM	BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO	
7:00 - 8:00	REGISTRATION							
8:00 - 9:00	Plenary talk # 4	<p align="center"><i>The hope for prophylactic vaccine for leishmaniasis</i></p> <p align="center">Dr. Abhay Satoskar The Ohio State University, USA</p> <p align="center">Presenter: Felix J. Tapia, Universidad Central de Venezuela, Venezuela</p>						
9:00 - 9:30	Successful experience #4	<p align="center">Dr. Fabiana Alves DNDi, Switzerland</p> <p align="center">Presenter: Dr. Felix J. Tapia, Universidad Central de Venezuela, Venezuela</p>						
9:30 - 10:00	COFEE BREAK							

FRIDAY (August 5th)

AUDITORIUM	BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO	
10:00 - 11:30	<p>Satelites symposium (sessions 33-38)</p> <p>Special Meeting #3</p>	<p>Symposium # 33:</p> <p>Experiences with mHealth in Leishmaniasis</p> <p>Chair: Dr. Carlos Rojas Universidad de Antioquia, Colombia</p> <p><i>1. Integrated approach to control Neglected Tropical Diseases of the skin (Skin NTDs App)</i> Dr. Jose Antonio Ruiz Postigo, WHO, Switzerland</p> <p><i>2. Leishcare®: A Software Designed for the Management of Individuals with leishmaniasis</i> Dr. Luciana de Almeida Silva Teixeira, Federal University of Triângulo Mineiro, Brazil</p> <p><i>3. mHealth follow-up of cutaneous leishmaniasis patients: a mixed methods community-based implementation study Guaral+ST App</i> Dr. Alexandra Cossio Duque, CIDEIM, Colombia</p>	<p>Symposium # 34:</p> <p>Empowering people with cutaneous leishmaniasis through interdisciplinary research and community-based interventions (ECLIPSE)</p> <p>Chair: Dr. Helen Price Keele University, UK</p> <p>Co-chair: Dr. Paulo Roberto Lima Machado Federal University of Bahia, Brazil</p> <p><i>1. Empowering people with cutaneous leishmaniasis: an introduction to the ECLIPSE programme</i> Dr. Helen Price, Keele University, UK</p> <p><i>2. Thinking beyond the clinical, parasitological and epidemiological aspects of cutaneous leishmaniasis in Sri Lanka</i> Dr. Suneth Agampodi, Rajarata University, Sri Lanka</p> <p><i>3. Meanings and experiences in CL from a community perspective: listening to the people</i> Dr. Leny Trad, Instituto de Saúde Coletiva, Universidade Federal da Bahia, Brazil</p> <p><i>4. Interdisciplinary training for community health workers and other health professionals: initiatives and challenges</i> Dr. Leo Pedrana, Instituto de Saúde Coletiva (ISC), Universidade Federal da Bahia (UFBA), Brazil</p> <p><i>5. The untold history of leishmaniasis in Sri Lanka</i> Dr. Kosala Weerakoon, Rajarata University, Sri Lanka</p>	<p>Symposium # 35:</p> <p>Data for decision making for VL elimination Sponsored by: CARE and The Bill and Melinda Gates Foundation</p> <p>Chair: Dr. Sridhar Srikantiah, CARE, India Co-chair: Satyabrata Routray, PATH, India</p> <p><i>1. KA-MIS development and applications in the post-elimination phase</i> Dr. Joy Bindroo, CARE, India</p> <p><i>2. Transmission dynamics: from epidemic cycles to elimination as a public health problem, and how to sustain the success in the future</i> Dr. Caryn Bern, University of California, USA</p> <p><i>3. PKDL as a challenge to VL elimination</i> Dr. Pushkar Dubey, CARE, India</p> <p><i>4. Modelling spatiotemporal patterns of visceral leishmaniasis incidence in India</i> Dr. Subramanian Swaminathan, ICMR-Vector Control Research Centre, India</p>	<p>Symposium # 36:</p> <p>Leishmaniasis and immunosuppression</p> <p>Chair: Dr. Javier Moreno Instituto de Salud Carlos III, Spain</p> <p><i>1. Biomarkers for the clinical management of immunosuppressed VL patients</i> Dr. Javier Moreno, Instituto de Salud Carlos III, Spain</p> <p><i>2. Study of experimental VL in pharmacologically immunosuppressed mice</i> Dr. Jose Carlos Solana, Instituto de Salud Carlos III, Spain</p> <p><i>3. Deployment-acquired asymptomatic Leishmania infantum infection followed by immunosuppression: How do patients fare?</i> Dr. Naomi E. Aronson, Uniformed Services University of the Health Sciences, USA</p>	<p>Symposium #37:</p> <p>Leishvet: Animal leishmaniasis: is a change of mind needed?</p> <p>LEISHVET</p> <p>Chair: Dr. Gad Baneth, The Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Israel</p> <p>Co-Chair: Dr. Gaetano Oliva, LEISHVET, Spain</p> <p><i>1. Canine leishmaniasis caused by Leishmania tropica and L. major – differences from L. infantum infection</i> Dr. Gad Baneth, The Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Israel</p> <p><i>2. Equine leishmaniasis caused by Leishmania infantum – clinical features, sub-clinical infection and diagnosis</i> Dr. Laia Solano-Gallego, Universitat Autònoma de Barcelona, Spain Dr. Gad Baneth, The Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Israel</p> <p><i>3. Epidemiology of animal leishmaniasis in Madrid area after the human leishmaniasis outbreak</i> Dr. Guadalupe Miró, LEISHVET, Spain</p> <p><i>4. The sand fly skin parasite interface</i> Dr. Patrick Bourdeau, Veterinary School of Nantes, School Nantes-Oniris - Nantes University, France Dr. Christine Petersen, Center for Emerging Infectious Diseases, University of Iowa, USA</p> <p><i>5. Concomitant infections in leishmaniasis: a forgotten problem (dog & cat)</i> Dr. Laia Solano-Gallego, Universitat Autònoma de Barcelona, Spain Dr. Gaetano Oliva, Università di Napoli Federico II, Italy</p> <p><i>6. Asymptomatic dog's infectiousness: is treatment necessary?</i></p>	<p>Symposium # 38</p> <p>The cutaneous leishmaniasis in the Maghreb region</p> <p>Chair: Dr. Mourad Mokni, University Tunis Al Manar 2, Tunisia. TBC</p> <p><i>1. GIS base enviromental risk mapping for surveillance and control of cutaneous leishmaniasis in Algeria: lessons learnt form the field</i> Dr. Harrat Zoubir, Institute Pasteur of Algeria, Algeria. TBC</p> <p><i>2. Genomics and data science applications for diagnosis of cutaneous leishmaniasis</i> Dr. Emna Harigua, Institut Pasteur de Tunis, Tunisia</p> <p><i>3. Cutaneous Leishmaniasis in the Maghreb: Publication metrics and collaboration opportunities</i> Dr. Issam Bennis, Mohammed VI University of Health Sciences, Morocco</p>	<p>Symposium # 44</p> <p>New hope for leishmaniasis: how to communicate to a broader non-scientific audience</p> <p>Chair: Marcela Victoria Dobarro, DNDi, Latin America</p> <p><i>1. A storytelling approach to social determinants of health related to leishmaniasis</i> Marcela Victoria Dobarro, DNDi, Latin America</p> <p><i>2. Strategic dissemination of research results: promoting positive impact on the population</i> Andrew J Wight, International Science Journalist based in Medellin, World Federation of Science Journalism</p> <p><i>3. Health and inequalities: a story of coca deforestation and leishmaniasis</i> Efrain Rincón Alvarez, Colombia</p> <p><i>4. Telling the story of leishmaniasis and war in Colombia: a book, a exhibit, and a policy brief</i> Lina Pinto-García, Institute for Science, Innovation and Society (InSIS) - University of Oxford, Interdisciplinary Center for Development Studies (CIDER) - Universidad de los Andes, Colombia</p>

FRIDAY (August 5th)

AUDITORIUM	BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO
11:30 - 13:00	<p>Symposium # 39:</p> <p>Drug resistance & quiescence: unravelling mechanisms and exploitation for better/new drugs</p> <p>Chair: Dr. Jean-Claude Dujardin Institute of Tropical Medicine of Antwerp, Belgium</p> <p><i>1. Genomic screens for drug resistance studies in Leishmania</i> Dr. Marc Ouellette, Université Laval, Canada</p> <p><i>2. Unraveling quiescent phenotypes as an adaptation to overcome drug pressure in Leishmania</i> Dr. Marlene Jara, Institute of Tropical Medicine of Antwerp, Belgium</p> <p><i>3. Tackling persists in Chagas disease drug discovery</i> Dr. Manu De Rycker, University of Dundee, UK</p> <p><i>4. Exploiting knowledge on drug resistance and tolerance in R&D for new drugs</i> Dr. Jadel Muller Kratz, DNDi, Switzerland</p> <p align="center">Satelites symposium (sessions 39-44)</p>	<p>Symposium # 40</p> <p>Immunological perspectives of leishmaniasis: beyond the Th1/Th2 paradigm</p> <p>Chair: Dr. Simona Stäger INRS - Centre Armand-Frappier Santé Biotechnologie, Canada</p> <p>Co-chair: Dr. Maria Adelaida Gómez CIDEIM, Colombia</p> <p><i>1. Tissue- and drug-specific transcriptome dynamics of CD4+ T cells during experimental visceral leishmaniasis</i> Dr. Christian Engwerda, QIMR Berghofer, Australia</p> <p><i>2. Oral tolerance induced by heat shock protein 65-producing Lactococcus lactis mitigates inflammation in Leishmania braziliensis infection</i> Dr. Claudia Ida Brodskyn, Instituto Gonçalo Moniz-FIOCRUZ, Brazil</p> <p><i>3. CD4 T cell maintenance in a chronic inflammatory environment</i> Dr. Simona Stäger, INRS - Centre Armand-Frappier Santé Biotechnologie, Canada</p> <p><i>4. Human macrophage response in the intrinsic susceptibility of L. (V.) panamensis to pentavalent antimony</i> Dr. Olga Fernandez, CIDEIM, Colombia</p>	<p>Symposium # 41:</p> <p>What can social sciences contribute to understanding and addressing leishmaniasis?: Examples from the field</p> <p>Chair: Dr. Mady Barbeitas Cermes 3/ Inserm (French National Institute of Health and Medical Research), France</p> <p>Co-chair: Lina Pinto-García Institute for Science, Innovation and Society (InSIS) - University of Oxford, Interdisciplinary Center for Development Studies (CIDER) - Universidad de los Andes, Colombia</p> <p><i>1. How neglected diseases can shape pharmaceutical markets? Local and global politics of innovation for leishmaniasis</i> Dr. Mady Barbeitas, Cermes 3/ Inserm (French National Institute of Health and Medical Research), France</p> <p><i>2. Back To Duty Rather Than Back To Health: Leishmaniasis And The Colombian Army</i> Dr. Lina Pinto-García, Institute for Science, Innovation and Society (InSIS) - University of Oxford, Interdisciplinary Center for Development Studies (CIDER) - Universidad de los Andes, Colombia</p> <p><i>3. History of the New World leishmaniasis: an overview</i> Dr. Jaime Larry Benchimol, FIOCRUZ, Brazil</p> <p><i>4. The orientalist's sore: biomedical discourses, capital and urban warfare in the colonial present</i> Dr. Louis-Patrick Haraoui, Université de Sherbrooke, Canada</p>	<p>Symposium # 42:</p> <p>Mucocutaneous leishmaniasis</p> <p>Chair: Dr. Jaime Soto FUNDERMA / Dermatological Hospital of Jorochito, Bolivia</p> <p><i>1. From the skin to the mucous membranes, an enigmatic journey</i> Dr. Daniel Holanda Barroso, Brazil</p> <p><i>2. How to reach the parasitological diagnosis in ML?</i> Dr. Lilian Motta, IOC/FIOCRUZ, Brazil</p> <p><i>3. Leishmania virus in ML</i> Dr. Maria Clara Echeverry, National University, Colombia</p> <p><i>4. Current status of treatment in ML</i> Dr. Alejandro Llanos-Cuentas, Peruvian University Cayetano Heredia, Peru</p> <p><i>5. Long-term follow-up in ML</i> Dr. Jaime Soto, FUNDERMA / Dermatological Hospital of Jorochito, Bolivia</p> <p><i>6. ML costs and their impact on program coverage</i> Dr. Glauca Fernandes, FIOCRUZ MINAS, Brazil</p> <p><i>7. Experience in the treatment of L. Mucosa in military personnel in Colombia</i> Dr. Claudia Cruz, Directorate of Health National Army of Colombia, Colombia</p>	<p>Symposium # 43:</p> <p>Animal leishmaniasis: is a change of mind needed?</p> <p>BRASILEISH</p> <p>Chair: Dr. Paulo Tabanez, Tabanez Veterinary Clinic and Brasileish, Brazil</p> <p>Co-chair: Dr. Octavio Estevez, Veterinaria del Oeste, Argentina</p> <p><i>1. Canine and human leishmaniasis in Latin America</i> Dr. Octavio Estevez, Veterinaria del Oeste, Argentina</p> <p><i>2. Canine leishmaniasis caused by Leishmania braziliensis</i> Dr. Filipe Dantas-Torres, Aggeu Magalhães Institute, FIOCRUZ, Brazil</p> <p><i>3. Diagnosis of Leishmania infantum infection in dogs in Latin America</i> Dr. Paulo Tabanez, Tabanez Veterinary Clinic, Brasileish, Brazil</p> <p><i>4. Clinical staging and management of Leishmania infantum infection in dogs in Latin America</i> Dr. Fabio dos Santos Nogueira, Faculty of Agricultural Sciences of Andradina, Brazil</p> <p><i>5. Canine leishmaniasis by Leishmania infantum in Paraguay</i> Dr. Antonio Rodríguez-Sánchez, Brasileish, Brazil</p> <p><i>6. Proposals for the control and management of canine leishmaniasis by Leishmania infantum in Latin America</i> Dr. Vitor Ribeiro, Virgílio Ribeiro de Menezes / Tereza Bonifácia Ribeiro, Brazil</p>	<p>Special meeting #2</p> <p>Access to medicines in Neglected Tropical Diseases</p> <p>Dr. German Velásquez, South Centre, France</p> <p>Presenter: Dr. Gabriela Delgado Universidad Nacional de Colombia Colombia"</p>	<p>Special Meeting #3</p> <p>The Last Mile: Strategic Humanitarian Technology Sponsored by: EOSYNC</p> <p>Chair: Dr. Michael Silva, EOSYNC, USA</p> <p>1. Dr. Gena Zischke, EOSYNC, USA</p> <p>2. Dr. Clark Madsen, EOSYNC, USA</p> <p>3. Dr. Michael Silva, EOSYNC, USA</p>
13:00 - 14:00	LUNCH						

FRIDAY (August 5th)

AUDITORIUM	BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO	
14:00 - 15:30	<p align="center">Round Tables (sessions 5-8)</p>	<p>RT # 5:</p> <p>VL/HIV coinfection: revised WHO guidelines and remaining challenges within the frame of the WHO 2021-2030 NTD roadmap</p> <p>Chair: Dr. Johan van Griensven, Institute of Tropical Medicine of Antwerp, Belgium</p> <p>1. VL/HIV coinfection: where do we stand Dr. Johan van Griensven, Institute of Tropical Medicine of Antwerp, Belgium</p> <p>2. Next steps to overcome remaining challenges: research priorities. Dr. Saurabh Jain, WHO, Switzerland</p> <p>3. Predicting visceral leishmaniasis in HIV infected patients in Ethiopia: first step towards a screen and treat strategy Dr. Ermias Diro, University of Washington, USA</p>	<p>RT # 6:</p> <p>Towards a consensus on Leishmania identification and characterization. Molecular markers for strain typing of Leishmania species: which are truly useful and in which regions or conditions</p> <p>Chair: Dr. Elisa Cupolillo FIOCRUZ, Brazil</p> <p>Co-chair: Dr. Jeffrey Shaw Sao Paulo University, Brazil</p> <p>Panelists:</p> <p>Dr. Paul Bates Lancaster University, UK</p> <p>Dr. Hugo Valdivia NAMRU, Peru</p> <p>Dr. Jeffrey Shaw Sao Paulo University, Brazil</p>	<p>RT #7:</p> <p>VL Elimination Program in Africa: envisioning the stakeholders perspective</p> <p>Sponsored by: The END Fund</p> <p>Chair: Dr. Jorge Alvar, DNDi, Switzerland</p> <p>Co-chair: Dr. Carol Karutu, The END Fund, Kenya</p> <p>1. Dr. Daniel Argaw, WHO, Switzerland</p> <p>2. Dr. Koert Ritmeijer, MSF, Netherlands</p> <p>3. Dr. Sheila Shawa, African Union Commission, Ethiopia</p> <p>4. Dr. Duncan Ochol, The END Fund, Kenya</p> <p>5. Bhupendra Tripathi, Infectious Diseases Cluster, India Country Office. Bill and Melinda Gates Foundation, India</p>	<p>RT #8:</p> <p>Canine Leishmaniasis</p> <p>Chair: Dr. Guadalupe Miró Leishvet, Spain</p> <p>Co-chair: Dr. Filipe dantas-Torres Aggeu Magalhães Institute, FIOCRUZ, Brazil</p> <p>Dr. Gad Baneth, The Koret School of Veterinary Medicine, The Hebrew University of Jerusalem</p> <p>Dr. Laia Solano-Gallego, Universitat Autònoma de Barcelona, Spain</p> <p>Dr. Guadalupe Miró, LEISHVET, Spain</p> <p>Dr. Patrick Bourdeau, Veterinary School of Nantes -ONIRIS - Nantes University, France</p> <p>Dr. Christine Petersen, University of Iowa, USA</p> <p>Dr. Gaetano Oliva, LEISHVET, Spain</p> <p>Dr. Octavio Estevez, Veterinaria del Oeste, Argentina</p> <p>Dr. Filipe Dantas-Torres, Aggeu Magalhães Institute, FIOCRUZ, Brazil</p> <p>Dr. Antonio Rodríguez-Sánchez, Brasileish, Brazil</p> <p>Dr. Paulo Tabanez, Tabanez Veterinary Clinic, Brasileish, Brazil</p> <p>Dr. Fabio Nogueira, Brasileish, Brazil</p> <p>Dr. Vitor Ribeiro, Brasileish, Brazil</p>			
15:30 - 16:30	<p align="center">Oral communications (sessions 29-35)</p>	<p>Oral communications Session #29</p> <p>Drug Discovery & Development</p> <p>Chair: Dr. Sara Maria Robledo, Pecet, Universidad de Antioquia, Colombia</p> <p>029-01 to 029-06</p>	<p>Oral communications Session #30</p> <p>Vectors & Reservoirs</p> <p>Chair: Dr. Pter Volf, Charles University Czech Republic</p> <p>030-01 to 030-06</p>	<p>Oral communications Session #31</p> <p>Immunology/Cell Biology/Pathogenesis</p> <p>Chair: Gabriela Delgado, Universidad Nacional de Colombia Colombia</p> <p>031-01 to 031-06</p>	<p>Oral communications Session #32</p> <p>Ecoepidemiology</p> <p>Chair: Daniel Salomón, National Institute of Tropical Medicine, INMeT, ANLIS, MoH Argentina</p> <p>032-01 to 032-06</p>	<p>Oral communications Session #33</p> <p>Molecular Biology</p> <p>Chair: Marcel Marin PECET-Universidad de Antioquia, Colombia</p> <p>033-01 to 033-06</p>	<p>Oral communications Session #34</p> <p>Diagnosis/Treatment and Resistance/Clinic</p> <p>Chair: Dr. Alexis Mendoza-León, Universidad Central de Venezuela, Venezuela</p> <p>034-01 to 034-06</p>	<p>Oral communications Session #35</p> <p>Pathogenesis</p> <p>Chair: Dr. Francehuli Dagger Universidad Central de Venezuela Venezuela</p> <p>035-01 to 035-06</p>

FRIDAY (August 5th)

AUDITORIUM	BOLIVAR - A	BOLIVAR - B	BOLIVAR - C	BOLIVAR - D	BOLIVAR - E	CARTAGENA	GUACAMAYO	
16:30 - 17:30	POSTER PRESENTATION Session P4 Canine leishmaniasis: P4-001 to P4-010 Drug Discovery & Development: P4-011 to P4-019 Prevention and Control: P4-020 to P4-030 Immunomodulation: P4-031 to P4-047 Omics: P4-048 to P4-064 Vectors: P4-065 to P4-074 Reservoirs: P4-075 to P4-092							
17:30 - 18:00	COFFEE BREAK							
18:00 - 19:00	Oral communications (sessions 36-41)	Oral communications Session #36 Drug Discovery & Development Chair: Sara Maria Robledo, Pecet, Universidad de Antioquia, Colombia 036-01 to 036-06	Oral communications Session #37 Immunology/Cell Biology/Pathogenesis Chair: Dr. Zelandia Fermín Universidad Central de Venezuela Venezuela 037-01 to 037-06	Oral communications Session #38 Immunology/Cell Biology/Pathogenesis Chair: Marcel Marin PECET-Universidad de Antioquia, Colombia 038-01 to 038-06	Oral communications Session #39 Epidemiology Chair: Dr. Sinval Pinto Brandão Filho Centro de Pesquisas Aggeu Magalhães FIOCRUZ Brazil 039-01 to 039-06	Oral communications Session #40 Vaccines Chair: Dr. Gabriela Delgado, Universidad Nacional de Colombia Colombia 040-01 to 040-06	Oral communications Session #41 Treatment Chair: Dr. Jaime Soto FUNDERMA / Dermatological Hospital of Jorochito Bolivia 041-01 to 041-06	

SATURDAY (August 6th)

AUDITORIUM		BOLIVAR
8:30 - 9:30	Plenary talk # 5:	<p align="center"><i>What will be next....</i></p> <p align="center">Dr. Nancy G. Saravia CIDEIM, Colombia</p> <p align="center">Presenter: Dr. Sara M. Robledo PECET-Universidad de Antioquia, Colombia</p>
9:30 - 11:00	Special meeting #4	<p align="center"><i>Health and social information systems in support of local health planning: issues and challenges</i></p> <p align="center">Chair: Dr. Antonio Jose Postigo, WHO, Switzerland</p> <p align="center"><i>1. Use of social and environmental indicators to identify local areas to carry out surveillance and control actions against visceral leishmaniasis in Brazil</i> Dr. Lucas Edel Donato, Ministry of Health, Brazil</p> <p align="center"><i>2. GIS-based environmental risk mapping for surveillance and control of cutaneous leishmaniasis in Algeria : lessons learnt from the field</i> Dr. Harrat Zoubir, Institut Pasteur, Algeria</p> <p align="center"><i>3. Web-based leishmaniasis surveillance system for cutaneous leishmaniasis in Iran: lessons learnt from the field</i> Dr. Mohammad Reza Shirzadi, Center for Communicable Diseases Control MOH, Iran</p>
11:00 - 11:30	COFEE BREAK	
11:30 - 12:00	<p align="center">AWARDS: Odile Bain Memorial Prize 2022/MDPI editorial</p>	

12:00 - 13:00	Closing lecture	Lessons learned from the Covid19 pandemic, the importance of public-private and state-university networks Dr. Martha Ospina National Health Institute, Colombia Presenter: Dr. Iván D. Vélez PECET, Universidad de Antioquia, Colombia
13.00 - 13:30	Closing remarks	